CAR-T cell therapy for autoimmune blood diseases
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This early-stage trial tests a new type of cell therapy (CAR-T cells) designed to treat severe autoimmune diseases where the immune system attacks the body's own organs. The therapy targets specific immune cells (B cells) that may be causing the disease. It may help patients who haven't improved with standard treatments or can't tolerate them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 3 years or older (5 years or older for some conditions)
- Confirmed diagnosis of one of these diseases: systemic lupus erythematosus (SLE), hard-to-treat kidney disease (SRNS), IgA nephropathy, scleroderma, or vasculitis
- Disease is severe or not responding to standard treatments despite adequate therapy for at least 3 months
- Heart, lung, liver, and kidney function must meet minimum standards (unless related to your autoimmune disease)
- No active infections, cancer, HIV, hepatitis B or C, or other conditions that would make the treatment unsafe
- If female and able to have children: willing to use birth control for 12+ months during and after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether specially-engineered immune cells (CAR-T cells) can help people with certain autoimmune diseases that haven't gotten better with standard treatments. The cells are designed to target and remove faulty B cells that are causing the immune system to attack the body.
This trial tests a new immune therapy called CAR T-cells that target two proteins (CD19 and BCMA) to treat autoimmune diseases like lupus, nephrotic syndrome, and others. It is for people whose standard treatments have not worked well enough.
This trial tests a new CAR-T cell therapy (a type of immune cell treatment) for people with certain autoimmune diseases, including lupus, scleroderma, and others. The goal is to see if the treatment can help control the disease.
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
This study tests an immune-cell treatment (CAR-T, called BRL-301) in people with certain autoimmune diseases that are active and hard to control. It may help your immune system calm down if standard treatments have not worked or your disease has returned.
This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.